Gressenberger, P.; Jud, P.; Kovacs, G.; Kreuzer, S.; Brezinsek, H.-P.; Guetl, K.; Muster, V.; Kolesnik, E.; Schmidt, A.; Odler, B.;
et al. Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. J. Pers. Med. 2021, 11, 600.
https://doi.org/10.3390/jpm11070600
AMA Style
Gressenberger P, Jud P, Kovacs G, Kreuzer S, Brezinsek H-P, Guetl K, Muster V, Kolesnik E, Schmidt A, Odler B,
et al. Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. Journal of Personalized Medicine. 2021; 11(7):600.
https://doi.org/10.3390/jpm11070600
Chicago/Turabian Style
Gressenberger, Paul, Philipp Jud, Gabor Kovacs, Sonja Kreuzer, Hans-Peter Brezinsek, Katharina Guetl, Viktoria Muster, Ewald Kolesnik, Albrecht Schmidt, Balazs Odler,
and et al. 2021. "Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis" Journal of Personalized Medicine 11, no. 7: 600.
https://doi.org/10.3390/jpm11070600
APA Style
Gressenberger, P., Jud, P., Kovacs, G., Kreuzer, S., Brezinsek, H.-P., Guetl, K., Muster, V., Kolesnik, E., Schmidt, A., Odler, B., Adelsmayr, G., Neumeister, P., Brcic, L., Zenz, S., Weber, K., Gary, T., Brodmann, M., Graninger, W. B., & Moazedi-Fürst, F. C.
(2021). Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. Journal of Personalized Medicine, 11(7), 600.
https://doi.org/10.3390/jpm11070600
